About the Recurrent Cancer Session
Recurrent cancer, the reappearance of cancer after a period of remission, poses a significant challenge in oncology. Despite initial treatments, cancer cells may persist undetected, eventually resurging. Addressing recurrence demands innovative approaches. Emerging therapies like immunotherapy harness the body's immune system to target cancer cells more effectively, potentially reducing recurrence rates. Precision medicine, tailoring treatment based on genetic profiles, offers promise in preventing relapse by identifying and targeting specific mutations driving cancer growth. Additionally, advances in early detection technologies, such as liquid biopsies capable of detecting minimal residual disease, hold potential in intercepting recurrence at its earliest stages. Combining these strategies with ongoing research into tumor microenvironments and cancer stem cells provides hope for more effective management of recurrent cancer in the future.
Topics Covered in Recurrent Cancer
Tumor Dormancy
Residual Disease Detection
Surveillance Imaging
Acquired Resistance
Salvage Therapy
Re-Irradiation
Related Scientific Sessions at CIOC 2027
Why Attend the Recurrent Cancer Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Recurrent Cancer work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Recurrent Cancer research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Recurrent Cancer track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Recurrent Cancer Conference 2027 — FAQs
What is the Recurrent Cancer track at CIOC 2027?
The Recurrent Cancer track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Recurrent Cancer. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Recurrent Cancer sessions?
Cancer researchers and clinicians, educators and students with an interest in Recurrent Cancer are all welcome — whether presenting or attending.
Can I present my research in the Recurrent Cancer track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Recurrent Cancer sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Recurrent Cancer track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.